Other Pharmaceuticals - Uzbekistan

Uzbekistan

The revenue in the Other Pharmaceuticals market in Uzbekistan is estimated to reach US$127.80m by the year 2024.
It is anticipated that there will be an annual growth rate of 6.57% (CAGR 2024-2029), leading to a market volume of US$175.70m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with an estimated value of US$260.50bn in 2024.
Due to the recent government initiatives promoting local production and investment, the Other Pharmaceuticals market in Uzbekistan is experiencing a surge in domestic pharmaceutical companies.

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Pharmaceuticals market in Uzbekistan is experiencing significant growth due to several factors.

Customer preferences: Customers in Uzbekistan have shown a preference for locally produced generic drugs over imported brands. This preference is due to the lower cost of locally produced drugs and the perception that they are of similar quality to imported brands.

Trends in the market: The Other Pharmaceuticals market in Uzbekistan is being driven by the increasing demand for generic drugs. The government has implemented policies to encourage the production of generic drugs in the country, which has led to the growth of local pharmaceutical companies. Additionally, the increasing prevalence of chronic diseases such as diabetes and cardiovascular disease has created a growing demand for pharmaceutical products.

Local special circumstances: Uzbekistan has a large population of over 34 million people, which provides a significant market for pharmaceutical companies. The country has a well-established healthcare system, with a network of hospitals and clinics throughout the country. However, the healthcare system is still developing, and there is a need for increased investment in healthcare infrastructure and services.

Underlying macroeconomic factors: Uzbekistan is experiencing strong economic growth, which is driving the growth of the Other Pharmaceuticals market. The government has implemented policies to encourage foreign investment in the country, which has led to the entry of international pharmaceutical companies into the market. Additionally, the government has implemented policies to promote the development of the healthcare sector, which has further supported the growth of the Other Pharmaceuticals market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.